Skip to main content
Top
Published in: International Cancer Conference Journal 1/2017

01-01-2017 | Case report

Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma

Authors: Mitsutaka Onoda, Ryo Sugimoto, Noriyuki Uesugi, Misato Takayama, Ei Shiomi, Renpei Kato, Yoichiro Kato, Ryo Takata, So Omori, Wataru Obara

Published in: International Cancer Conference Journal | Issue 1/2017

Login to get access

Abstract

Squamous cell carcinoma of the prostate is a rare tumor. It has been typically described as an aggressive cancer, with a median survival time of 14 months. We present a case of locally advanced squamous cell carcinoma of the prostate with a regional lymph node metastasis. The patient received a novel combination chemotherapy regimen, docetaxel, cisplatin, and 5-fluorouracil, with radiotherapy to the whole pelvis and prostate. He was subsequently treated with seven courses of docetaxel, cisplatin, and 5-fluorouracil chemotherapy without any severe adverse events. We identified a 60.1 % reduction in the prostatic tumor, and the lymph node metastasis was shrunk after chemotherapy. A needle biopsy of the prostate after chemotherapy revealed no malignancy. No recurrence has been observed for 24 months. A combination of docetaxel, cisplatin, and 5-fluorouracil chemotherapy and radiotherapy might be an effective therapy for squamous cell carcinoma of the prostate.
Literature
1.
go back to reference Mott LJ (1979) Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature. J Urol 121:833–835PubMed Mott LJ (1979) Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature. J Urol 121:833–835PubMed
2.
go back to reference Moskovitz B, Munichor M, Bolkier M et al (1993) Squamous cell carcinoma of the prostate. Urol Int 51:181–183CrossRefPubMed Moskovitz B, Munichor M, Bolkier M et al (1993) Squamous cell carcinoma of the prostate. Urol Int 51:181–183CrossRefPubMed
4.
5.
go back to reference Munoz F, Franco P, Ciammella P et al (2007) Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiat Oncol 2:15CrossRefPubMedPubMedCentral Munoz F, Franco P, Ciammella P et al (2007) Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiat Oncol 2:15CrossRefPubMedPubMedCentral
6.
go back to reference Uchibayashi T, Hisazumi H, Hasegawa M et al (1997) Squamous cell carcinoma of the prostate. Scand J Urol Nephrol 31:223–224CrossRefPubMed Uchibayashi T, Hisazumi H, Hasegawa M et al (1997) Squamous cell carcinoma of the prostate. Scand J Urol Nephrol 31:223–224CrossRefPubMed
7.
8.
go back to reference Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159CrossRefPubMedPubMedCentral Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159CrossRefPubMedPubMedCentral
9.
go back to reference Culine S, El-Demery M, Lamy PJ et al (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178:844–848 (discussion 8) CrossRefPubMed Culine S, El-Demery M, Lamy PJ et al (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178:844–848 (discussion 8) CrossRefPubMed
Metadata
Title
Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma
Authors
Mitsutaka Onoda
Ryo Sugimoto
Noriyuki Uesugi
Misato Takayama
Ei Shiomi
Renpei Kato
Yoichiro Kato
Ryo Takata
So Omori
Wataru Obara
Publication date
01-01-2017
Publisher
Springer Japan
Published in
International Cancer Conference Journal / Issue 1/2017
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0266-6

Other articles of this Issue 1/2017

International Cancer Conference Journal 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine